MedMira Inc (MIR) - Total Assets
Based on the latest financial reports, MedMira Inc (MIR) holds total assets worth CA$3.58 Million CAD (≈ $2.59 Million USD) as of January 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MedMira Inc book value and equity for net asset value and shareholders' equity analysis.
MedMira Inc - Total Assets Trend (2000–2025)
This chart illustrates how MedMira Inc's total assets have evolved over time, based on quarterly financial data.
MedMira Inc - Asset Composition Analysis
Current Asset Composition (July 2025)
MedMira Inc's total assets of CA$3.58 Million consist of 43.4% current assets and 56.6% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0.4% |
| Accounts Receivable | CA$1.32 Million | 35.8% |
| Inventory | CA$206.07K | 5.6% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$2.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how MedMira Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MedMira Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MedMira Inc's current assets represent 43.4% of total assets in 2025, a decrease from 74.3% in 2000.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2025, up from -164.4% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 35.8% of total assets.
MedMira Inc Competitors by Total Assets
Key competitors of MedMira Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
MedMira Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.09 | 0.08 |
| Quick Ratio | 0.06 | 0.08 | 0.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-23.49 Million | CA$-19.85 Million | CA$-15.68 Million |
MedMira Inc - Advanced Valuation Insights
This section examines the relationship between MedMira Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 8.22 |
| Asset Growth Rate (YoY) | -39.3% |
| Total Assets | CA$3.68 Million |
| Market Capitalization | $30.27 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values MedMira Inc's assets at a significant premium (8.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: MedMira Inc's assets decreased by 39.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MedMira Inc (2000–2025)
The table below shows the annual total assets of MedMira Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-07-31 | CA$3.68 Million ≈ $2.66 Million |
-39.34% |
| 2024-07-31 | CA$6.07 Million ≈ $4.39 Million |
+66.21% |
| 2023-07-31 | CA$3.65 Million ≈ $2.64 Million |
-4.64% |
| 2022-07-31 | CA$3.83 Million ≈ $2.77 Million |
-1.56% |
| 2021-07-31 | CA$3.89 Million ≈ $2.81 Million |
+14.55% |
| 2020-07-31 | CA$3.40 Million ≈ $2.46 Million |
+1244.88% |
| 2019-07-31 | CA$252.52K ≈ $182.67K |
-16.08% |
| 2018-07-31 | CA$300.91K ≈ $217.68K |
-55.33% |
| 2017-07-31 | CA$673.71K ≈ $487.35K |
-22.55% |
| 2016-07-31 | CA$869.90K ≈ $629.28K |
-51.23% |
| 2015-07-31 | CA$1.78 Million ≈ $1.29 Million |
-3.16% |
| 2014-07-31 | CA$1.84 Million ≈ $1.33 Million |
+57.86% |
| 2013-07-31 | CA$1.17 Million ≈ $844.08K |
-60.72% |
| 2012-07-31 | CA$2.97 Million ≈ $2.15 Million |
+99.06% |
| 2011-07-31 | CA$1.49 Million ≈ $1.08 Million |
+162.62% |
| 2010-07-31 | CA$568.18K ≈ $411.01K |
+8.55% |
| 2009-07-31 | CA$523.41K ≈ $378.63K |
-37.18% |
| 2008-07-31 | CA$833.19K ≈ $602.71K |
-70.91% |
| 2007-07-31 | CA$2.86 Million ≈ $2.07 Million |
-28.54% |
| 2006-07-31 | CA$4.01 Million ≈ $2.90 Million |
+180.64% |
| 2005-07-31 | CA$1.43 Million ≈ $1.03 Million |
-15.67% |
| 2004-07-31 | CA$1.69 Million ≈ $1.23 Million |
-28.26% |
| 2003-07-31 | CA$2.36 Million ≈ $1.71 Million |
-29.80% |
| 2002-07-31 | CA$3.36 Million ≈ $2.43 Million |
+11.05% |
| 2001-07-31 | CA$3.03 Million ≈ $2.19 Million |
-16.26% |
| 2000-07-31 | CA$3.62 Million ≈ $2.62 Million |
-- |
About MedMira Inc
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or who… Read more